Control of endemic glycopeptide-resistant enterococci

被引:36
作者
Dembry, LM
Uzokwe, K
Zervos, MJ
机构
[1] WILLIAM BEAUMONT HOSP,DIV INFECT DIS,ROYAL OAK,MI 48073
[2] WAYNE STATE UNIV,SCH MED,DEPT INTERNAL MED,DETROIT,MI 48201
[3] WAYNE STATE UNIV,SCH MED,DIV INFECT DIS,DETROIT,MI 48201
[4] YALE UNIV,SCH MED,NEW HAVEN,CT
关键词
D O I
10.2307/30141928
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 [公共卫生与预防医学]; 120402 [社会医学与卫生事业管理];
摘要
OBJECTIVE: To evaluate the epidemiology of, and control measures for, vancomycin-resistant Enterococcus (VRE) in a renal unit. DESIGN: A 3-month, prospective, prevalence culture survey of patients on a 24-bed renal unit. SETTING: A 975-bed community teaching hospital. PATIENTS: Patients admitted to the renal unit over a 3-month period. Patients identified with VRE were each matched with four patients without VRE isolated over the study period. INTERVENTIONS/CONTROL MEASURES: Resistant-organism barrier precautions. To eradicate carriage of VRE, two patients with VRE stool colonization were treated with 5 days of oral doxycycline (100 mg twice per day) and rifampin (300 mg/day). RESULTS: Seven patients with VRE (8 isolates) were identified. Five isolates were Enterococcus faecium (vancomycin MIC=16 to 256 mu g/mL), two were Enterococcus faecalis (MICs=16 and 124 mu g/mL), and one was Enterococcus gallinarum (MIC=8.0 mu g/mL). Eradication of carriage with VRE was accomplished in two patients treated with doxycycline and rifampin. In the final 30 days of the culture survey and at 9 months, there were no further patients with VRE identified. CONCLUSIONS: Resistant-organism precautions and elimination of patient carriage may be useful measures for controlling the spread of low-prevalence endemic vancomycin-resistant Enterococcus (Infect Control Hosp Epidemiol 1996;17:286-292).
引用
收藏
页码:286 / 292
页数:7
相关论文
共 36 条
[1]
PHARMACOKINETIC STUDIES OF RIFAMPICIN IN THE ELDERLY [J].
ADVENIER, C ;
GOBERT, C ;
HOUIN, G ;
BIDET, D ;
RICHELET, S ;
TILLEMENT, JP .
THERAPEUTIC DRUG MONITORING, 1983, 5 (01) :61-65
[2]
AROCELLA G, 1983, REV INFECT DIS S, V5, P428
[3]
EMERGENCE AND NOSOCOMIAL TRANSMISSION OF AMPICILLIN-RESISTANT ENTEROCOCCI [J].
BOYCE, JM ;
OPAL, SM ;
POTTERBYNOE, G ;
LAFORGE, RG ;
ZERVOS, MJ ;
FURTADO, G ;
VICTOR, G ;
MEDEIROS, AA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (05) :1032-1039
[4]
OUTBREAK OF MULTIDRUG-RESISTANT ENTEROCOCCUS-FAECIUM WITH TRANSFERABLE VANB CLASS VANCOMYCIN RESISTANCE [J].
BOYCE, JM ;
OPAL, SM ;
CHOW, JW ;
ZERVOS, MJ ;
POTTERBYNOE, G ;
SHERMAN, CB ;
ROMULO, RLC ;
FORTNA, S ;
MEDEIROS, AA .
JOURNAL OF CLINICAL MICROBIOLOGY, 1994, 32 (05) :1148-1153
[5]
NOSOCOMIAL ACQUISITION OF BETA-LACTAMASE NEGATIVE, AMPICILLIN-RESISTANT ENTEROCOCCUS [J].
CHIRURGI, VA ;
OSTER, SE ;
GOLDBERG, AA ;
MCCABE, RE .
ARCHIVES OF INTERNAL MEDICINE, 1992, 152 (07) :1457-1461
[6]
CLONAL SPREAD OF VANCOMYCIN-RESISTANT ENTEROCOCCUS-FAECIUM BETWEEN PATIENTS IN 3 HOSPITALS IN 2 STATES [J].
CHOW, JW ;
KURITZA, A ;
SHLAES, DM ;
GREEN, M ;
SAHM, DF ;
ZERVOS, MJ .
JOURNAL OF CLINICAL MICROBIOLOGY, 1993, 31 (06) :1609-1611
[7]
DEMBRY LM, 1994, INFECT CONT HOSP EP, V15, P48, DOI 10.1086/646817
[8]
MOLECULAR TYPING OF AMPICILLIN-RESISTANT, NON-BETA-LACTAMASE-PRODUCING ENTEROCOCCUS-FAECIUM ISOLATES FROM DIVERSE GEOGRAPHIC AREAS [J].
DONABEDIAN, SM ;
CHOW, JW ;
BOYCE, JM ;
MCCABE, RE ;
MARKOWITZ, SM ;
COUDRON, PE ;
KURITZA, A ;
PIERSON, CL ;
ZERVOS, MJ .
JOURNAL OF CLINICAL MICROBIOLOGY, 1992, 30 (11) :2757-2761
[9]
AN OVERVIEW OF NOSOCOMIAL INFECTIONS, INCLUDING THE ROLE OF THE MICROBIOLOGY LABORATORY [J].
EMORI, TG ;
GAYNES, RP .
CLINICAL MICROBIOLOGY REVIEWS, 1993, 6 (04) :428-442
[10]
IDENTIFICATION OF ENTEROCOCCUS SPECIES ISOLATED FROM HUMAN INFECTIONS BY A CONVENTIONAL TEST SCHEME [J].
FACKLAM, RR ;
COLLINS, MD .
JOURNAL OF CLINICAL MICROBIOLOGY, 1989, 27 (04) :731-734